This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


1zd2

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:1zd2.gif|left|200px]]
+
{{Seed}}
 +
[[Image:1zd2.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1zd2| PDB=1zd2 | SCENE= }}
{{STRUCTURE_1zd2| PDB=1zd2 | SCENE= }}
-
'''Human soluble epoxide hydrolase 4-(3-cyclohexyluriedo)-ethanoic acid complex'''
+
===Human soluble epoxide hydrolase 4-(3-cyclohexyluriedo)-ethanoic acid complex===
-
==Overview==
+
<!--
-
X-ray crystal structures of human soluble epoxide hydrolase (sEH) complexed with four different dialkylurea inhibitors bearing pendant carboxylate "tails" of varying length have been determined at 2.3-3.0 A resolution. Similarities among inhibitor binding modes reinforce the proposed roles of Y381 and/or Y465 as general acids that protonate the epoxide ring of the substrate in concert with nucleophilic attack of D333 at the electrophilic epoxide carbon. Additionally, the binding of these inhibitors allows us to model the binding mode of the endogenous substrate 14,15-epoxyeicosatrienoic acid. Contrasts among inhibitor binding modes include opposite orientations of inhibitor binding in the active-site hydrophobic tunnel. Alternative binding orientations observed for this series of inhibitors to human sEH, as well as the binding of certain dialkylurea inhibitors to human sEH and murine sEH, complicate the structure-based design of human sEH inhibitors with potential pharmaceutical applications in the treatment of hypertension. Thus, with regard to the optimization of inhibitor designs targeting human sEH, it is critical that human sEH and not murine sEH be utilized for inhibitor screening, and it is critical that structures of human sEH-inhibitor complexes be determined to verify inhibitor binding orientations that correlate with measured affinities.
+
The line below this paragraph, {{ABSTRACT_PUBMED_16322563}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 16322563 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_16322563}}
==Disease==
==Disease==
Line 31: Line 35:
[[Category: Morisseau, C.]]
[[Category: Morisseau, C.]]
[[Category: Domain-swapped dimer]]
[[Category: Domain-swapped dimer]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 17:28:49 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 12:33:16 2008''

Revision as of 09:33, 28 July 2008

Image:1zd2.png

Template:STRUCTURE 1zd2

Contents

Human soluble epoxide hydrolase 4-(3-cyclohexyluriedo)-ethanoic acid complex

Template:ABSTRACT PUBMED 16322563

Disease

Known disease associated with this structure: Hypercholesterolemia, familial, due to LDLR defect, modifier of OMIM:[132811]

About this Structure

1ZD2 is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.

Reference

Human soluble epoxide hydrolase: structural basis of inhibition by 4-(3-cyclohexylureido)-carboxylic acids., Gomez GA, Morisseau C, Hammock BD, Christianson DW, Protein Sci. 2006 Jan;15(1):58-64. Epub 2005 Dec 1. PMID:16322563

Page seeded by OCA on Mon Jul 28 12:33:16 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/1zd2"
Personal tools